What Shattuck Labs Stock Topped the Market on Monday

STTK surged nearly 5% Monday after pulling dual buy ratings from major analysts. Raymond James issued a strong buy with an $18 price target—more than double the stock's $7.90 close—while TD Cowen initiated coverage with a buy rating.

The bullish thesis centers on SL-325, the company's lead candidate for autoimmune and inflammatory diseases. The drug is currently in Phase 2b trials for inflammatory bowel disease and represents a first-in-class approach to the condition. Analysts see a total addressable market exceeding $20 billion for the treatment.

The synchronized endorsements mark a notable shift in Wall Street attention for the clinical-stage biotech. Raymond James' price target implies 128% upside from Monday's closing level, reflecting confidence in the drug's commercial potential despite the inherent execution risk of mid-stage trials.